GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moolec Science SA (NAS:MLEC) » Definitions » Capex-to-Revenue

Moolec Science (Moolec Science) Capex-to-Revenue : -0.03 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Moolec Science Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Moolec Science's Capital Expenditure for the three months ended in Dec. 2023 was $0.01 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.25 Mil.

Hence, Moolec Science's Capex-to-Revenue for the three months ended in Dec. 2023 was -0.03.


Moolec Science Capex-to-Revenue Historical Data

The historical data trend for Moolec Science's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moolec Science Capex-to-Revenue Chart

Moolec Science Annual Data
Trend Jun21 Jun22 Jun23
Capex-to-Revenue
- - 0.20

Moolec Science Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.06 -0.03

Competitive Comparison of Moolec Science's Capex-to-Revenue

For the Biotechnology subindustry, Moolec Science's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moolec Science's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moolec Science's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Moolec Science's Capex-to-Revenue falls into.



Moolec Science Capex-to-Revenue Calculation

Moolec Science's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.179) / 0.905
=0.20

Moolec Science's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0.008) / 0.252
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moolec Science  (NAS:MLEC) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Moolec Science Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Moolec Science's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Moolec Science (Moolec Science) Business Description

Traded in Other Exchanges
N/A
Address
17, Boulevard F.W. Raiffeisen, Luxembourg, LUX, L-2411
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system.